Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (551-560 of 674) with videos related to

Pageof 68
Sort By:
Scientific Reports|March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcomaChristopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Nature Immunology|January 12, 2026
PARP inhibition generates enhanced CD8<sup>+</sup> central memory T cells by transcriptional and metabolic reprogrammingWael Traboulsi, Pankaj Gaur, Subhadip Kundu, et al.
Journal of Clinical Pharmacology|December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trialR Barroso-Sousa, W T Barry, H Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2018
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)Mark Jesus M Magbanua, Hope S Rugo, Denise M Wolf, et al.
Drug and Alcohol Dependence|March 18, 2019
Predictors of timely opioid agonist treatment initiation among veterans with and without HIVJessica J Wyse, Jonathan L Robbins, Kathleen A McGinnis, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2025
Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancerNikita Sushentsev, Gregory Hamm, Roido Manavaki, et al.
Journal of the American Society for Mass Spectrometry|November 25, 2025
Automatic Tissue Detection for Mass Spectrometry ImagingJames Denholm, Lucy E Flint, Jack Richings, et al.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Pageof 68

Showing results (551-560 of 674) with videos related to

Sort By:
Pageof 68
Scientific Reports|March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcomaChristopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Nature Immunology|January 12, 2026
PARP inhibition generates enhanced CD8<sup>+</sup> central memory T cells by transcriptional and metabolic reprogrammingWael Traboulsi, Pankaj Gaur, Subhadip Kundu, et al.
Journal of Clinical Pharmacology|December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trialR Barroso-Sousa, W T Barry, H Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2018
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)Mark Jesus M Magbanua, Hope S Rugo, Denise M Wolf, et al.
Drug and Alcohol Dependence|March 18, 2019
Predictors of timely opioid agonist treatment initiation among veterans with and without HIVJessica J Wyse, Jonathan L Robbins, Kathleen A McGinnis, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2025
Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancerNikita Sushentsev, Gregory Hamm, Roido Manavaki, et al.
Journal of the American Society for Mass Spectrometry|November 25, 2025
Automatic Tissue Detection for Mass Spectrometry ImagingJames Denholm, Lucy E Flint, Jack Richings, et al.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Pageof 68